Sage Therapeutics and Biogen pursue FDA approval for zuranolone
/cloudfront-us-east-2.images.arcpublishing.com/reuters/IXYUV47KYRP5DGR3BXFFW4NLJE.jpg "Sage Therapeutics to cut about 188 jobs after depression drug setback | Reuters")
Sage Therapeutics to cut about 188 jobs after depression drug setback | Reuters
Sage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus - Tinnitus Treatment Report
Sage Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics (@SageBiotech) / X
Sage Therapeutics (@SageBiotech) / X
Layoffs as Sage Therapeutics reshuffles CNS pipeline
While Sage Therapeutics sees a window for depression drug, market is skeptical - MedCity News
Biotech layoffs 2023: Sage Therapeutics cuts nearly half its staff in wake of partial FDA rejection - Boston Business Journal
Sage Therapeutics - Timberline Construction
Sage Therapeutics slumps, Biogen bounces
Rx Product News: April 2023
Sage Therapeutics — ramon leander
Goldman Sachs Maintains Sage Therapeutics (SAGE) Neutral Recommendation
Sage Therapeutics stock falls after stock offering, Q3 miss | Seeking Alpha
/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/5L4UQNLAORLRMH6HCPVSUTPQUE.JPEG "Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe")
Sage Therapeutics to lay off about 40 percent of its workforce - The Boston Globe
Biopharmaceutical Company for Brain Health Disorders - Sage Therapeutics
Sage tumbles to record low on clinical depression pill setback | Reuters
Sage Therapeutics Archives - DelveInsight
Sage Therapeutics wins priority review for intravenous postpartum depression drug - MassDevice
Sage Therapeutics Restructures To Support ZURZUVAE Launch | Contract Pharma
Sage Therapeutics CEO on drugs in development, addressing mental health
